Showing 1080 – 1090 of 1303 results
-
Nkarta Inc Initiation
William Blair initiated research coverage of Nkarta, Inc. (NKTX $14.27), a clinical-stage company focused on the development and commercialization of genetically engineered allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapies for the treatment of cancer.
-
Cyxtera Technologies Inc Initiation
William Blair initiated research coverage of Cyxtera Technologies, Inc. (CYXT $11.56), a global carrier-neutral data center operator focused on retail colocation and interconnection services.
-
Arcellx Inc Initiation of Research Coverage
William Blair initiated research coverage of Arcellx, Inc. (ACLX $16.97), a clinical-stage company focused on the development and commercialization of first-in-class adaptive immune cell therapies that can be readily activated and reprogrammed.
-
William Blair Initiates Coverage of Symbotic Inc.
William Blair initiated research coverage of Symbotic Inc. (SYM $17.93), which provides a robotics and automation-based solution for warehouse order fulfillment.
-
Alnylam Pharmaceuticals Inc Initiation
William Blair initiated research coverage of Alnylam Pharmaceuticals, Inc. (ALNY $131.52), the premier commercial-stage siRNA therapeutics company. Alnylam has four approved therapies and over eight additional candidates in clinical development.
-
Sierra Wireless Inc Initiation
William Blair initiated research coverage of Sierra Wireless, Inc. (SWIR $16.45), a preferred IoT solutions provider that combines edge devices (e.g., cellular routers/gateways and modules), connectivity services, software, security, and a secure cloud platform to simplify IoT deployments.
-
argenx SE Initiation
William Blair initiated research coverage of argenx SE ($393.26), a global immunology company focused on antibody-based therapies to treat rare autoimmune diseases.
-
NewAmsterdam Pharma Company NV Initiation
William Blair initiated research coverage of NewAmsterdam Pharma Company N.V. (NAMS $12.00). NewAmsterdam Pharma is developing the CETP inhibitor obicetrapib to reduce the risk of cardiovascular events.
-
Entrada Therapeutics Inc Initiation
William Blair initiated research coverage of Entrada Therapeutics, Inc. (TRDA $14.51), a preclinical-stage company focused on the development of next-generation intracellular therapeutics using cell-targeting and endosomal escape technology.
-
Forge Global Holdings Inc Initiation
William Blair initiated research coverage of Forge Global Holdings, Inc. (FRGE $3.27), a leading financial technology company that provides critical infrastructure, data services, and technology solutions to transact in the private markets.